- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Menarini sponsored speakers and an exhibition stand at a BJMA UK meeting. The Panel found the event’s main purpose was social/cultural with…
A patient complained about Prolia patient information, a German leaflet being supplied, and alleged missing side-effect information and “yellow marker/black triangle” issues.…
A Pulse “Quick Guide” funded by Bausch & Lomb was found to resemble independent editorial content and included misleading claims about skin-to-muscle…
Large Milan meeting billed as an advisory board was ruled not genuine; UK HCPs were paid to attend what was deemed promotional…
MIMS “abbreviated” CosmoCol ad included pack size/cost and other claims, so needed prescribing info. Both the ad and a leavepiece failed to…
A representative alleged rushed SOP training and answer-changing to secure 100% scores before a PMCPA audit. Panel found validation across six SOPs…
Janssen admitted a ‘Dear Doctor’ letter said Invokana was available for GPs to prescribe in certain CCGs, but in 39 CCGs only…
Roche admitted a British Journal of Haematology issue carried four pages of MabThera advertising due to a printer error (a bound-in card…
A public complaint about trial transparency found one Nplate trial with UK involvement was disclosed late on ClinicalTrials.gov, breaching Clauses 21.3 and…
Flynn sent a “Dear Doctor” letter during an Equasym supply shortage, promoting Medikinet/Medikinet XL. Panel found no issue with referencing the shortage,…
At ESC 2015, Daiichi-Sankyo emailed delegates photos taken in a stand photo booth. PMCPA ruled the emailed photos were a gift supplied…
A promotional email said Abasaglar was approved on the NHS Sunderland CCG formulary. The Panel found this misleading because no such formulary…
A pharmacist complained that Lincoln Medical’s website listed POM brand names and indications without access controls. The Panel ruled this amounted to…
At EULAR 2016, an IL‑6 disease-awareness stand (plus linked symposium/posters) was ruled to have prepared the market for unlicensed sarilumab. Breaches of…
A health professional alleged multiple Pfizer website items had out-of-date prescribing information. Breaches were found for Vfend and Depo‑Provera (Clause 4.1) and…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.